Arbutus Biopharma (ABUS)
Develops chronic HBV therapies while monetizing legacy lipid-nanoparticle IP.
$5.01
vs last close+0.01 (+0.20%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 71.79% | 142.04M shares | |
|---|---|---|---|
| 182 holders · as of Jun 30, 2026 | |||
| Insiders | 0.33% | 647.4K shares | |
| 5 holders · as of Feb 2, 2026 | |||
| Strategic holders | 19.64% | 38.85M shares | |
| 1 holder · as of Feb 25, 2025 | |||
| Other | 8.24% | 16.31M shares | |
| remainder | |||
197.85M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
182 holders · 142.04M shares · 37 new positions · 101 increased · 39 reduced · 26 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Two Seas Capital LP | 19.10M | 9.65% | +538.0K | Aug 12, 2026 |
| Morgan Stanley | 17.70M | 8.95% | −8.19M | Aug 13, 2026 |
| Whitefort Capital Management, LP | 15.79M | 7.98% | +863.4K | Aug 14, 2026 |
| BlackRock, Inc. | 13.77M | 6.96% | +799.1K | Aug 7, 2026 |
| State Street Corp | 7.87M | 3.98% | +1.53M | Aug 7, 2026 |
| Rubric Capital Management LP | 7.53M | 3.81% | +906.5K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 7.01M | 3.54% | +321.8K | Aug 13, 2026 |
| Barclays PLC | 4.21M | 2.13% | −108.2K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Roivant Sciences Ltd. | 20.50% | 38.85M | 13D | Feb 25, 2025 |
| Morgan Stanley | 13.50% | 25.91M | 13G | Feb 11, 2026 |
| Two Seas Capital LP | 9.40% | 18.56M | 13G | May 15, 2026 |
| Whitefort Capital Master Fund, LP | 8.00% | 15.79M | 13G | Sep 4, 2026 |
| Whitefort Capital GP, LLCincl. Whitefort Capital Management, LP, Whitefort Capital Master Fund, LP +3 more | 8.00% | 15.79M | 13D | Apr 28, 2026 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.